Literature DB >> 29807752

Targeted Glycemic Control for Adult Patients With Type 2 Diabetes Mellitus in the Acute Care Setting.

Ali Pourmand1, Maryann Mazer-Amirshahi2, Amy Caggiula3, Aria Nawab3, Christopher Payette3, Samuel Johnson3.   

Abstract

Diabetes mellitus and complications arising from the disease are a leading cause of morbidity and mortality worldwide. With increasing prevalence over the past 50 years and an estimated 20% of health-care spending dedicated to the disease, diabetes is considered by many to be a true public health emergency. Several protocols and management options exist to maximize glycemic control in the ambulatory setting, but the optimal glucose level in critically and noncritically ill inpatients is still debated. This review examines the evidence behind differing degrees of glycemic control across a variety of hospital settings and clinical scenarios. Patients presenting to the emergency department who are found to be hyperglycemic pose additional management challenges for clinicians. In this setting, no consensus exists for optimal serum glucose level and safe discharge parameters.
Copyright © 2018 Diabetes Canada. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  blood glucose; contrôle de la glycémie; diabetes mellitus; diabète sucré; glucose sanguin; glycemic control; hyperglycemia; hyperglycémie; hypoglycemia; hypoglycémie; insulin; insuline

Mesh:

Substances:

Year:  2018        PMID: 29807752     DOI: 10.1016/j.jcjd.2018.01.015

Source DB:  PubMed          Journal:  Can J Diabetes        ISSN: 1499-2671            Impact factor:   4.190


  2 in total

1.  Effect of Average Blood Glucose Greater Than 140 mg/dL on Adverse Patient Outcomes in Adult Medical/Surgical Patients.

Authors:  Morgan A Wynes; Jaclyn A Boyle
Journal:  Innov Pharm       Date:  2021-02-15

2.  Relationship between transforming growth factor-β1 and type 2 diabetic nephropathy risk in Chinese population.

Authors:  Tianbiao Zhou; Hong-Yan Li; Hongzhen Zhong; Zhiqing Zhong
Journal:  BMC Med Genet       Date:  2018-11-20       Impact factor: 2.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.